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The development of severe hyperbilirubinemia after cardiac surgery performed with cardiopulmonary bypass (CPB) is a challenging complication because its mechanism is still 
not completely clarified, and there are so few specific therapies 
available for acute hepatobiliary injury [1].
Post-operative mortality well correlates with increasing 
total bilirubin values, particularly for bilirubin-associate acute 
kidney tubular necrosis [2]. The difficulty to reduce mortality 
is partially a consequence of not completely understood 
physiopathology [3-6]. It is obvious that long-lasting CPB 
plays an important role, in association with hemodilution, 
hypotension, ischemia-reperfusion, and increasing hematic level 
of endogenous catecholamine with reduction of hepatic blood 
flow [7]. These mechanisms, in the majority of cases, do not 
have any consequence because hepatocytes and biliary system 
well tolerate the reduction of blood flow, but rarely, and not 
exclusively following long-lasting CPB, total post-operative 
serum bilirubin can rise >3 mg/dl determining the “cholestatic 
post-cardiac surgery syndrome” [8-10].
Coupled plasma filtration adsorption (CPFA) is an 
extracorporeal technique used for blood purification in septic 
shock, severe sepsis, and multiple organ dysfunction syndrome, 
while the possibility of the resin in the cartridge to retain 
bilirubin was described as the second option of the technique 
and consequently used with success to treat hyperbilirubinemia 
after hepatic transplantation and multiple organ failure from 
hypoxic hepatitis [11,12]. We present the case of an 80-year-old 
cardiac patient with multiple organ failure, who was managed 
successfully using CPFA to remove conjugated bilirubin.
CASE REPORT
An 80-year-old male was scheduled for mini-sternotomy aortic 
valve replacement to correct severe stenosis with biological 
“suture-less” prosthesis in January 2018. He was diabetic, with 
pre-operative bilirubin value 0.4 mg/dl, recent evidence of 
severe dyspnea, and preoperative echocardiography showing 
low left ventricular ejection fraction. Operation was uneventful 
(cardiopulmonary by-pass time 59 min and aortic cross-clamp 
time 32 min), and the patient was moved to Intensive Care Unit 
(ICU) with satisfactory vital and hemodynamic parameters 
(invasive blood pressure 125/75 mmHg, central venous pressure 
9 mmHg, and arterial oxygen saturation 100%) obtained with 
minimal inotropic support (dobutamine 4 µg/kg/min).
During the 1st postoperative day (POD 1), we noticed 
worsening hemodynamic profile, treated using different 
and stronger pharmacological support (noradrenaline 
0.05 µg/kg/min and adrenaline 0.1 µg/kg/min). Transesophageal 
echocardiography showed acute systo-diastolic failure due to 
severe aortic paravalvular leak, so the patient was scheduled for 
immediate sternotomy reoperation (cardiopulmonary by-pass 
time 97 min and aortic cross-clamp time 27 min) and returned to 
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ICU with increased inotropic support (adrenaline 0.15 µg/kg/min 
and noradrenaline 0.15 µg/kg/min).
On POD 3, we performed continuous veno-venous 
hemodiafiltration to reduce serum creatinine (4.0 mg/dl) and 
serum urea (151 mg/dl); during the following days, urine output 
and consequently patient’s kidney function parameters were 
satisfactory without new renal replacement therapy (Fig. 1). 
In the course of hospitalization, the patient became jaundiced 
with progressive total serum bilirubin increased to 24.50 mg/dl 
(conjugated bilirubin 19.80 mg/dl and unconjugated bilirubin 
4.70 mg/dl) on POD 16, and consequently, we performed CPFA, 
four cycles between POD 16 and POD 18, with total serum 
bilirubin reduction to 8.20 (conjugated bilirubin 6.36 mg/dl and 
unconjugated bilirubin 1.84 mg/dl) and three cycles between POD 
22 and POD 24; as a consequence of first-treatment rebound due 
to extracellular shift of bilirubin, total serum bilirubin increases to 
18.50 mg/dl (conjugated bilirubin 14.95 mg/dl and unconjugated 
bilirubin 3.55 mg/dl) with following reduction to 9.1 mg/dl 
(conjugated bilirubin 6.45 mg/dl and unconjugated bilirubin 
2.65 mg/dl) (Fig. 1).
We used four-pump, modular extracorporeal blood 
purification system (Lynda® Bellco spa) consisting of plasma 
filter (0.45 m2 polyethersulfone) to separate plasma from blood, 
unselective hydrophobic resin cartridge (140 ml for 70 g, with 
a surface of about 700 m2/g), and synthetic, high-permeability, 
1.4 m2 polyethersulfone hemofilter where plasma treated 
from unselective hydrophobic resin cartridge came back with 
blood cells coming from plasma filter [13]. A follow-up of the 
patient was done after 3 months of discharge; the patient was 
asymptomatic with actual total serum bilirubin 0.6 mg/dl.
DISCUSSION
The pathogenesis of “cholestatic post-cardiac surgery 
syndrome” is still not completely understood but seems to be 
multifactorial [1,14,15]. Several factors are main predictors of post-
operative hyperbilirubinemia: Overproduction of bilirubin caused by 
blood transfusions during and shortly after surgery [14,15], decreased 
intraoperative hepatic flow, acute systo-diastolic cardiac failure, and 
administration of drugs that constrict the hepatic vasculature such as 
norepinephrine and epinephrine [7], and hemolysis after prolonged 
CPB and aortic cross-clamp time [10,14,15].
We observed only mild hepatic transaminases elevation but 
marked total serum bilirubin increase, and these laboratory data 
showed that biliary system was more sensible than hepatocyte 
to ischemic damage because it worked against gradient to pump 
conjugate bilirubin from hepatocytes into biliary canaliculi 
and, consequently, the first sign of hepatic sufferance was total 
and particularly conjugated bilirubin increase. Meticulous 
post-operative pharmacological management, optimizing 
hemodynamics to maintain satisfactory cardiac output, and using 
a renal dosage of dopamine and continuous furosemide infusion 
were useful to preserve diuresis and avoid progression to hepatic 
renal failure.
We performed seven cycles of CPFA (lasting 6 h each-one 
until all the resins were adsorbed on the sorbent cartridge) using 
four-pump, modular extracorporeal blood purification system 
(Lynda® Bellco spa), with blood flow rate of 150 ml/min, plasma 
flow rate of 30 ml/min (20% of blood flow rate), and ultrafiltration 
rate of 35 ml/kg/h.
The observed reduction of total serum bilirubin was 67% from 
peak value after the first treatment (four cycles of CPFA) and 
51% after the second one (three cycles of CPFA) with definitive 
stable bilirubinemia of 3.0 mg/dl (conjugated bilirubin 2.27 mg/dl 
and unconjugated bilirubin 0.73 mg/dl) when the patient was 
discharged from the ICU. The effectiveness of our treatment is 
clinically proved indeed the patient is well and alive 3 months 
after the discharge from ICU, with actual total serum bilirubin 
0.6 mg/dl.
CONCLUSION
The development of severe hyperbilirubinemia after cardiac surgery 
performed with CPB is a rare and challenging complication. The 
results of our report suggest that CPFA is a good hemodepurative 
technique to manage successfully severe hyperbilirubinemia of 
“cholestatic post-cardiac surgery syndrome.”
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